News
Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJj. 1991;303:288. (14) Lui SF, Leung CB, Li PK, Lai KN.
Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other ... NeoRecormon, Dynepo) or up to 42 days post injection in the case of MIRCERA.
MIRCERA is a new long-acting chemically synthesized erythropoiesis-stimulating agent (ESA). The positive opinion recommends the following use of MIRCERA in the treatment of anaemia associated with ...
Mircera is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. It is formulated as a sterile, preservative-free ...
FDA delay on Mircera a reprieve for Amgen, J&J . The FDA delayed an approval decision on Roche’s Mircera pending a fall advisory committee review, spelling temporary relief for marketers of similar ...
The FDA has approved Roche's anemia drug Mircera, but don't look for any big new product launches soon. Last month Amgen won a patent infringement case on the therapy. And Roche is studying its ...
The judge refereeing the turf battle between Roche and Amgen over anemia meds has taken a time-out to consult the experts. Judge William Young said he's grappling "with complex issues" in the patent ...
In Europe, analysts expect Mircera to eventually replace those of Roche's older, similar, anemia treatment NeoRecormon, which had sales of more than CHF1.5 billion in 2006. Including an anemia ...
Amgen Inc. said a federal court granted the biotechnology company a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., while also upholding a ...
injection with darbepoetin alfa as more painful than MIRCERA injections. The study. In a randomized, placebo-controlled, single centre, single blind study, healthy subjects (81 completed the study) ...
BASEL, Switzerland, May 25 /PRNewswire/ -- Roche announced today that it has received a positive opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results